UNLOCK THE IQIRVO EFFECT

Transform PBC treatment expectations with proven efficacy and an established safety profile1

UNLOCK THE IQIRVO EFFECT

Transform PBC treatment expectations with proven efficacy and an established safety profile1

The first-and-only FDA-approved treatment in PBC with PPAR alpha + delta activation1,2

Blue IQIRVO checkmark icon

Clear efficacy

IQIRVO is the only second-line therapy with a 47% treatment difference over UDCA alone1,3,4

51% of patients achieved biochemical response with IQIRVO (n=55/108) 
vs 4% on UDCA alone (n=2/53)1

See biochemical response data
Blue IQIRVO checkmark icon

Consistent response

Biochemical response achieved regardless of baseline ALP with IQIRVO vs 0% response for UDCA with ALP >2 x ULN1,2

See subgroup data
Blue IQIRVO checkmark icon

Symptom data

Data on the reduction of pruritus and fatigue across multiple scales2,5

IQIRVO has been prescribed by over 3,000 PBC treaters1,2

Data on file, June 2026

1-on-1 support icon

Dedicated 1-on-1 patient support to answer questions, navigate coverage, and assist with access and affordability

Explore support with IPSEN CARES®
Downloadable resources icon

Download resources to help you get patients started

See what’s available
Request a rep icon

Connect with an Ipsen representative

Request a rep

ALP=alkaline phosphatase; PBC=primary biliary cholangitis; PPAR=peroxisome proliferator–activated receptor; UDCA=ursodeoxycholic acid; ULN=upper limit of normal.

References: 1. IQIRVO [package insert]. Ipsen Biopharmaceuticals, Inc. Cambridge, MA. 2. Data on file. Ipsen Biopharmaceuticals, Inc. 3. Nevens F, Andreone P, Mazzella G, 
et al; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631-643. 4. Hirschfield GM, Bowlus CL, Mayo MJ, et al; RESPONSE Study Group. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783-794. 5. Kowdley KV, Bowlus CL, Levy C, et al; ELATIVE Study Investigators’ Group. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795-805.

Indication and Important Safety Information

Indication

IQIRVO® (elafibranor) is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Limitations of Use

Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Important Safety Information

Myalgia, Myopathy, and Rhabdomyolysis: Rhabdomyolysis resulting in acute kidney injury occurred in one IQIRVO-treated patient who had cirrhosis at baseline and was also taking a stable dose of an HMG-CoA reductase inhibitor (statin). Myalgia or myopathy, with or without CPK elevations, occurred in patients treated with IQIRVO alone or treated concomitantly with a stable dose of an HMG-CoA reductase inhibitor. Assess for myalgia and myopathy prior to IQIRVO initiation. Consider periodic assessment (clinical exam, CPK measurement) during treatment with IQIRVO, especially in those who have signs and symptoms of new onset or worsening of muscle pain or myopathy. Interrupt IQIRVO treatment if there is new onset or worsening of muscle pain, or myopathy, or rhabdomyolysis. Patients concomitantly taking peroxisome proliferator–activated receptor (PPAR)-alpha agonists (e.g., fenofibrate, fenofibric acid) may have an increased risk of muscle injury. Monitor for signs and symptoms of muscle injury during concomitant use with IQIRVO.

Fractures: Fractures occurred in 6% of IQIRVO-treated patients compared to no placebo-treated patients. Consider the risk of fracture in the care of patients treated with IQIRVO and monitor bone health according to current standards of care.

Adverse Effects on Fetal and Newborn Development: IQIRVO may cause fetal harm when administered during pregnancy. For females of reproductive potential, verify that the patient is not pregnant prior to initiation of therapy. IQIRVO may reduce the effectiveness of hormonal contraceptives containing ethinyl estradiol. Advise females of reproductive potential to avoid use of hormonal contraceptives containing ethinyl estradiol and to use alternative contraception, including progestin-only contraceptives containing levonorgestrel/norgestrel, intrauterine systems, or effective non-hormonal contraceptives during treatment with IQIRVO and for 3 weeks after the last dose of IQIRVO.

Drug-Induced Liver Injury: Drug-induced liver injury occurred in one patient who took IQIRVO 80 mg once daily and two patients who took IQIRVO at 1.5-times the recommended dosage, of which one presented with autoimmune-like hepatitis. The median time to onset of elevation in liver tests was 85 days. Obtain baseline clinical and laboratory assessments at treatment initiation with IQIRVO and monitor thereafter according to routine patient management. Interrupt IQIRVO treatment if liver tests (ALT, AST, total bilirubin [TB], and/or alkaline phosphatase [ALP]) worsen, or the patient develops signs and symptoms consistent with clinical hepatitis (e.g., jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting IQIRVO. Patients concomitantly taking PPAR-alpha agonists (e.g., fenofibrate, fenofibric acid) and/or PPAR-gamma agonists (e.g., pioglitazone, rosiglitazone) may have an increased risk of liver injury. Monitor for signs and symptoms of liver injury during concomitant use with IQIRVO.

Hypersensitivity Reactions: Hypersensitivity reactions have occurred in a clinical trial with IQIRVO at 1.5-times the recommended dosage. Three patients (0.2%) had rash or unspecified allergic reaction that occurred 2 to 30 days after IQIRVO initiation. Hypersensitivity reactions resolved after discontinuation of IQIRVO and treatment with steroids and/or antihistamines. If a severe hypersensitivity reaction occurs, permanently discontinue IQIRVO. If a mild or moderate hypersensitivity reaction occurs, interrupt IQIRVO and treat promptly. Monitor the patient until signs and symptoms resolve. If a hypersensitivity reaction recurs after IQIRVO rechallenge, then permanently discontinue IQIRVO.

Biliary Obstruction: Avoid use of IQIRVO in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt IQIRVO and treat as clinically indicated.

The most common adverse events (occurring in ≥5% of patients) were weight gain, diarrhea, abdominal pain, nausea, vomiting, arthralgia, constipation, muscle injury, fracture, gastroesophageal reflux disease, dry mouth, weight loss, and rash.

Drug-Drug Interactions

Effects of IQIRVO on Other Drugs

IQIRVO is a weak CYP3A4 inducer. A clinical interaction study demonstrated that co-administration of IQIRVO and a combined oral hormonal contraceptive produced a decrease of ethinylestradiol. Switch to progestin-only products containing levonorgestrel/norgestrel, intrauterine systems, or effective non-hormonal contraceptives during treatment with IQIRVO and for at least 3 weeks after the last dose.

Co-administration of IQIRVO and HMG-CoA reductase inhibitors (statins): Monitor for signs and symptoms of muscle injury. Consider periodic assessment (clinical exam, CPK) during treatment. Interrupt IQIRVO treatment if there is new onset or worsening of muscle pain
or myopathy.

Effects of Other Drugs on IQIRVO

Strong CYP2C8 inhibitors: Avoid concomitant use of IQIRVO with strong CYP2C8 inhibitors (e.g., gemfibrozil). If concomitant use cannot be avoided, monitor patients for adverse reactions.

Co-administration of IQIRVO with other PPAR-alpha agonists: Monitor for signs and symptoms of liver injury and muscle injury.

Co-administration of IQIRVO with PPAR-gamma agonists: Monitor for signs and symptoms of liver injury.

Co-administration of IQIRVO with rifampin, an inducer of metabolizing enzymes, may reduce the systemic exposure of elafibranor and its active metabolite via increased metabolism and may result in delayed or suboptimal biochemical response. Monitor the biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin during treatment with IQIRVO.

Bile acid sequestrants may interfere with IQIRVO absorption and systemic exposure, which may reduce efficacy. Administer IQIRVO at least 4 hours before or after a bile acid sequestrant, or at as great an interval as possible.

Use in Special Populations

Pregnancy: Based on data from animal reproduction studies, IQIRVO may cause fetal harm when administered during pregnancy. There are insufficient data from human pregnancies exposed to IQIRVO to allow an assessment of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There is a pregnancy safety study for IQIRVO. If IQIRVO is administered during pregnancy, healthcare providers should report IQIRVO exposure by contacting Ipsen Biopharmaceuticals, Inc. at 1-844-990-0239 or www.iqirvopregnancyregistry.com

Lactation: There are no data available on the presence of IQIRVO or its metabolites in human milk, or on effects of the drug on the breastfed infant or the effects on milk production. IQIRVO is not recommended during breastfeeding and for at least 3 weeks following the last dose of IQIRVO because the risk to the breastfed child cannot be excluded.

Females and Males of Reproductive Potential: IQIRVO may cause fetal harm when administered to pregnant women. Verify the pregnancy status of females of reproductive potential prior to initiating IQIRVO. Advise females of reproductive potential to use effective contraception during treatment with IQIRVO and for 3 weeks after the final dose.

You are encouraged to report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127.

Please see full Prescribing Information for IQIRVO.